NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Tonix Pharmaceuticals Holding Corp. TNXP
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$13.1M
▲ 29.8% vs FY2024
EPS · FY25
$-14.57
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-64.5%
Net margin · FY25
-946.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 13.1M
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 946 cents on every revenue dollar this year.
Per share
USD -14.57
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-64.5%
Return on equity, FY2025
ROE
Operating margin-959.1%
Net margin-946.2%
Return on assets-56.4%
Each USD of equity lost 64 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -224.2M
Share of profit-0.0%
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 277.2M
total assets, end of FY2025
Total assetsUSD 277.2M
EquityUSD 245.2M
CashUSD 207.6M
Current ratio7.42×
Equity funds 88% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−14.57
−176.60
−14720.25
−20.01
−8.10
−0.55
−19.33
−259.85
−31.69
−15.41
−28.62
−2.77
−3.37
−5.58
−3.24
−0.18
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−64.5
−106.1
−74.6
−51.8
−60.2
−104.0
−173.0
−108.1
−84.5
−118.4
−125.9
−129.6
−291.4
·
·
·
·
·
Shares out B
0.01
0.00
0.00
0.01
0.02
0.21
0.01
0.00
0.00
0.00
0.00
0.01
0.01
0.00
0.00
0.02
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed